Clinical Trials on Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies
Total 20 results
-
University Hospital, MontpellierCompletedPatients Recieving Anti-PD-1 or Anti-PD-L1 ImmunotherapiesFrance
-
Novartis PharmaceuticalsActive, not recruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationSpain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India
-
Beijing Friendship HospitalCompletedCamrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.Biliary Tract Cancer | Capecitabine | Targeted Molecular Therapy | Anti-PD-1 TherapyChina
-
Chinese PLA General HospitalRecruitingHodgkin Lymphoma | Anti-PD-1 Antibody ResistantChina
-
Sun Yat-sen UniversityRecruitingImmunotherapy | DMMR Colorectal Cancer | Anti PD-1China
-
Shanghai Jiao Tong University School of MedicineRecruitingOral Squamous Cell Carcinoma | Anti-PD-1 | Neoadjvant Therapy | Anti-VEGFRChina
-
Ascendis Pharma Oncology Division A/SRecruitingAdvanced Solid Tumor | Metastatic Solid Tumor | Platinum-resistant Ovarian Cancer | Locally Advanced Solid Tumor | Post Anti-PD-1 Melanoma | 2L+ Cervical Cancer | Neoadjuvant Melanoma | Neoadjuvant Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Small Cell...United States, Australia, Korea, Republic of
-
Peking Union Medical College HospitalRecruitingAnlotinib | Anti-PD-1 Antibody | Advanced Pancreatic CancerChina
-
West China HospitalFirst Affiliated Hospital of Chongqing Medical University; Sichuan Cancer Hospital... and other collaboratorsRecruitingRectal Cancer | Radiotherapy | Anti-PD-1 Antibody | MSI-H | Mmr DeficiencyChina
-
The First Hospital of Jilin UniversityNot yet recruitingLocally Advanced Rectal Cancer | Anti-PD-1 | Total Neoadjuvant TreatmentChina
-
Lei LiCompletedChemotherapy | Recurrent Cervical Carcinoma | Immunotherapy | Anti-PD-1 Antibody | Persistent Advanced Cervical CarcinomaChina
-
Zhejiang Cancer HospitalNot yet recruitingGastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and SurgeryChina
-
Shanghai Jiao Tong University School of MedicineRecruitingChemotherapy | Oral Squamous Cell Carcinoma | Anti-PD-1 | Neoadjvant TherapyChina
-
Lei LiRecruitingChemotherapy | Recurrent Cervical Carcinoma | Immune Checkpoint Inhibitors | Anti-PD-1 Antibody | Persistent Advanced Cervical Carcinoma | Albumin-bound PaclitaxelChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingRecurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
-
Fudan UniversityNot yet recruitingthe Efficacy and Safety of PD-1 Inhibitors With or Without Radiotherapy in Patients With Advanced MelanomaChina
-
Second Affiliated Hospital, School of Medicine,...RecruitingOvarian Cancer | Neoadjuvant Chemotherapy | Anti-PD-1 | Neoadjuvant ImmunotherapyChina
-
The Second Affiliated Hospital of Chongqing Medical...Guizhou Provincial People's Hospital; The Affiliated Hospital Of Southwest...Not yet recruitingChronic Hepatitis b | Anti-PD-1 Antibody | Peg-IFNαChina
-
The Second Affiliated Hospital of Chongqing Medical...Guizhou Provincial People's Hospital; The Affiliated Hospital Of Southwest...Not yet recruitingChronic Hepatitis b | Anti-PD-1 AntibodyChina
-
Lei LiUnknownCamrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine CarcinomasChemotherapy | Recurrent Cervical Carcinoma | Adverse Drug Event | Cervical Neuroendocrine Carcinoma | Objective Response Rate | Advanced Cervical Carcinoma | Anti-pd-1 AntibodyChina